Literature DB >> 6684559

Comparison of anthracycline concentrations in S180 cell lines of varying sensitivity.

J M Siegfried, T R Tritton, A C Sartorelli.   

Abstract

Sublines of sarcoma 180 (S180) of varying sensitivity to adriamycin (ADR) have been selected in culture. The degree of resistance of these sublines ranged from 6- to 125-fold above that of parent S180 cells. ADR-resistant sublines demonstrated comparable degrees of cross-resistance to daunomycin (DNR), marcellomycin and AD 32, but each subline showed a uniform degree of tolerance toward actinomycin D and vincristine. Compared to the anthracycline-sensitive parent tumor, a 40% decrease in the intracellular steady-state level of [3H]-daunomycin was observed in all sublines regardless of the degree of resistance. The level of cell-associated DNR and ADR observed after administration of equipotent concentrations of drug was different for each cell line and increased in proportion to the drug concentration. Thus, altered drug permeability appeared to be of minimal importance in the expression of high levels of resistance. In addition, the extent of DNR metabolism by the anthracycline-resistant sublines was not sufficiently different from that seen in parent S180 cells to account for the observed tolerance to these agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684559     DOI: 10.1016/0277-5379(83)90039-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  12 in total

1.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells.

Authors:  A T Fojo; J Whang-Peng; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

3.  Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

Authors:  A W Himmelmann; S Danhauser-Riedl; G Steinhauser; R Busch; E J Modest; A Noseda; J Rastetter; W R Vogler; W E Berdel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer.

Authors:  J A Moscow; A J Townsend; M E Goldsmith; J Whang-Peng; P J Vickers; R Poisson; S Legault-Poisson; C E Myers; K H Cowan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

5.  Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.

Authors:  S Stallard; J G Morrison; W D George; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.

Authors:  J Sonka; U Schossig; M Vogt-Schaden; M Volm
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.

Authors:  C Etiévant; O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.

Authors:  L S Borman; W G Bornmann; M E Kuehne
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Molecular cytogenetics of multiple drug resistance.

Authors:  P V Schoenlein
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.

Authors:  R Ganapathi; H Schmidt; D Grabowski; M Melia; N Ratliff
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.